Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples

Breast Cancer Clinical Trial

Official title:

Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01034033
• Other study ID #: IRB-11872
• Secondary ID: SU-11022007-786B
• Status: Recruiting
• Start date: August 2001
• Est. completion date: January 2099

Study information

• Verified date: January 2024
• Source: Stanford University
• Contact: Meredith Mills
• Phone: (650) 724-5223
• Email: bluett[@]stanford.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to try to understand the biology of development of breast, ovarian, fallopian tube, peritoneal or endometrial cancer from persons at high genetic risk for these diseases. The influence of environmental factors on cancer development in individuals and families will be studied. The efficacy of treatments for these diseases will be evaluated.

Description:

1. To establish a demographic database to evaluate the efficacy of medical interventions in patients and relatives who carry BRCA1 and 2 mutations and to compare these outcomes to patients who do not carry a BRCA1 or 2 mutation.

2. To obtain blood samples from patients who undergo genetic testing to a) evaluate the incidence of genetic modifier polymorphisms involved in the development of cancer in BRCA1 and 2 mutation carriers and to compare this incidence to non-BRCA 1 and 2 carriers. b) to understand the interaction of genetic modifiers and BRCA1 and 2 in the development of cancer. c) to determine the effect of environmental influences on the incidence of polymorphisms in genetic modifiers and on the penetrance of BRCA1 and 2 mutations by linking information from our demographic database to blood samples and

3. To obtain tumor tissue from BRCA1 and 2 carriers to utilize for gene expression studies.

4. To establish a cohort of sporadic breast cancer patients, or women with no family history of cancer in a first degree relative, to serve as a comparison group to women with strong family history of breast cancer.

5. To establish a cohort of healthy volunteers without personal or family history of cancer to serve as a comparison group to women with sporadic and familial breast cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3300
• Est. completion date: January 2099
• Est. primary completion date: January 2099
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

I. Women who have a high risk of developing breast or ovarian cancer due to a known germline mutation in the BRCA1/2, PTEN, CDH1, or TP53 cancer susceptibility genes, or due to strong family history of either breast or ovarian cancer, in the absence of known cancer susceptibility gene mutation.

II. Women who are approaching surgery for resection of a pelvic mass, which is considered suspicious for neoplasia by radiologic or clinical criteria; such women may or may not also meet criteria for inclusion in group I.

Related Conditions & MeSH terms

• Breast Cancer
• Gynecologic Cancers
• Ovarian Cancer
• Ovarian/Peritoneal/Fallopian Cancer

Locations

Country	Name	City	State
United States	Stanford University School of Medicine	Stanford	California

Sponsors (3)

Lead Sponsor	Collaborator
Stanford University	Breast Cancer Research Foundation, Susan G. Komen Breast Cancer Foundation

Country where clinical trial is conducted

United States,